<DOC>
	<DOCNO>NCT02399657</DOCNO>
	<brief_summary>A Single Arm , Single Dose Study Evaluate Effect intravitreal dexamethasone implant ( OzurdexÂ® ) hard exudate diabetic macular edema .</brief_summary>
	<brief_title>Effect Dexamethasone Implant Hard Exudate Complicated With Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic macular edema ( DME ) important vision threaten complication diabetes mellitus . Laser photocoagulation , vitrectomy , intravitreal steroid injection intravitreal antiVEGF ( anti vascular endothelial growth factor ) injection use treatment DME . Sustained release intravitreal dexamethasone implant know effective reduce central retinal thickness gain vision DME . Although hard exudate macula important pathology DME , impact intravitreal dexamethasone implant hard exudate study yet . Therefore investigator design descriptive study reveal hard exudate change DME eye treat intravitreal dexamethasone implant .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients diagnose CSME ( clinically significant macular edema ) hard exudate within 1500 micrometer foveal center 2 . Those BCVA ( best correct visual acuity ) study eye 0.06 ( 20/320 ) 0.5 ( 20/40 ) 3 . Those central macular thickness OCT 300 micrometer 4 . If eye eligible , eye hard exudate select ( contralateral eye treat corticosteroid Ozurdex focal laser photocoagulation , antiVEGF ( vascular endothelial growth factor ) injection allow contralateral eye ) 1 . Those CSME without hard exudate 2 . Those macular edema relate diabetic retinopathy ( e.g . AMD ( agerelated macular degeneration ) , uveitis , retinal vein occlusion untreated malignant hypertension ) 3 . Those history Intraocular surgery ( e.g . cataract surgery ) within 3 month 4 . Those visual acuity contralateral eye le 0.1 ( 10/100 ) 5 . Those received focal laser treatment macula within 3 month 6 . Those intravitreal antiVEGF agent injection within 3 month 7 . Those intravitreal triamcinolone injection within 6 month 8 . Those ophthalmologic disease affect visual acuity ( e.g . central corneal opacity , cataract change lens center ) 9 . Those severe systemic disease ( e.g . uncontrolled DM , hypertension , cardiovascular disease , cerebrovascular disease ) 10 . Those refuse submit write consent 11 . Those understand content clinical study cooperate clinical trial 12 . Those pregnant lactating woman 13 . Those history vitrectomy 14 . Those require systemic corticosteroid immunosuppressive agent treatment 15 . Those ban use Ozurdex Ocular infection periocular infection Advanced glaucoma Hypersensitivity dexamethasone component Ozurdex Posterior lens capsule rupture Aphakia Anterior chamber intraocular lens posterior capsule rupture</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>macular edema</keyword>
	<keyword>hard exudate</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>implant</keyword>
</DOC>